- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00126360
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
Pilot for a Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Ant-Oestrogen Therapy Delayed Until After Radiotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Adjuvant radiotherapy is well established as the primary modality to enhance local control in breast cancer. The use of adjuvant hormone therapy such as tamoxifen has shown to improve local control to a relatively minor amount on its own and does enhance local control of adjuvant radiotherapy. There is however, conflicting in vitro and clinical data regarding the effects of different sequences on tamoxifen and radiotherapy in terms of both local control and enhancement of radiotherapy toxicities.
Aromatase inhibitors such as anastrazole are establishing themselves as a class of drug superior to tamoxifen for the control of estrogen dependent breast cancers and overall are better tolerated with the exception of greater bone loss.
As the key question is whether the sequencing of the aromatase inhibitor anastrozole alters local control by acting as an enhancer of the radiation breast cancer cell kill, it is therefore the aim of this study to compare 3 months of anastrozole prior to radiotherapy versus 3 months of anastrozole after radiotherapy with a specific objective of reducing the baseline ratio of in- field radiotherapy failure from 6% to 3%.This pilot study is preliminary to a planned long term study to investigate local failure.
For the pilot a period of 6 months with all contributing centres open will provide a good test of recruitment matching estimates. 100 patients will provide a good sample to compare to the 270 tamoxifen treated women in the breast boost study for quality of life. It will also provide a 95% CI on the proportion of complying women in the order of ± 5% if 85 to 90 % of women comply.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Ass. Prof. Peter H Graham, MBBS FRANZCR
- Phone Number: +61 293503934
- Email: GrahamP@sesahs.nsw.gov.au
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2217
- Recruiting
- St George Hospital
-
Contact:
- Peter Graham, MBBS FRANZCR
- Phone Number: +61 2 9350 3912
- Email: GrahamP@sesahs.nsw.gov.au
-
Sydney, New South Wales, Australia, 2170
- Not yet recruiting
- Liverpool Hospital
-
Contact:
- Dr Geoff Delaney, MBBS FRANZCR
- Phone Number: +61 29828 5276
- Email: Geoff.Delaney@swsahs.nsw.gov.au
-
Principal Investigator:
- Dr Geoff Delaney, MBBS FRANZCR
-
Sydney, New South Wales, Australia, 2560
- Not yet recruiting
- Campbelltown Hospital
-
Contact:
- Dr George Papadatos, MBBS FRANZCR
- Phone Number: +61 246344355
- Email: George.papadatos@swsahs.nsw.gov.au
-
Principal Investigator:
- Dr George Papadatos, MBBS FRANZCR
-
-
Queensland
-
Brisbane, Queensland, Australia, 4102
- Not yet recruiting
- Princess Alexandra Hospital
-
Contact:
- Dr Jennifer Harvey, MBBS FRANZCR
- Phone Number: +61 732402 111
- Email: J.Harvey@mailbox.uq.edu.au
-
Principal Investigator:
- Dr Jennifer Harvey, MBBS FRANZCR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or more years. No upper limit.
- Post total mastectomy or lumpectomy. All planned surgery complete.
- Margins clear (no tumour contacting the inked margin)
- Tumour oestrogen or progesterone receptor positive
- Planned dose to irradiated volumes at least the biological equivalent of 45 Gy in 25 fractions or more.
- ECOG 0-2
- Patients post menopausal using same criteria as ATAC study.
- Written informed consent
Exclusion Criteria:
- Previous radiotherapy to the area to be treated.
- Previous invasive malignancy within 5 years of current breast cancer diagnosis with the exception of cervix in-situ or skin cancer other than melanoma.
- Patients with clinical evidence of metastatic disease.
- Previous hormonal breast therapy.
- Ongoing hormone replacement therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Local failure within irradiation volume
|
Secondary Outcome Measures
Outcome Measure |
---|
Early quality of life
|
Lung fibrosis
|
Also demonstration of recruitment capacity at lead trial centres
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ass. Prof. Peter H Graham, MBBS FRANZCR, Cancer Care Centre, St George Hospital, Sydney
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Anastrozole
Other Study ID Numbers
- STARS-Pilot (05/55 Graham)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Timing of Anastrozole in respect to radiotherapy
-
US Department of Veterans AffairsThe Cleveland Clinic; Case Western Reserve UniversityCompletedDiabetes MellitusUnited States
-
King Abdullah International Medical Research CenterCompletedType1diabetes | Fasting HypoglycemiaSaudi Arabia
-
University of Castilla-La ManchaMinisterio de Economía y Competitividad, Spain; Servicio de Salud de Castilla-La...RecruitingExercise Training | Fasting, Intermittent | Metabolic Syndrome, Protection Against | Metformin | Angiotensin Hypertension | Statins | Angiotensin-Converting-Enzyme InhibitorSpain
-
Johns Hopkins UniversityVital StrategiesCompletedCardiovascular Diseases | Hypertension | Blood Pressure | Cardiovascular Risk FactorUnited States
-
Hull University Teaching Hospitals NHS TrustNational Institute for Health Research, United Kingdom; University of York; South... and other collaboratorsCompletedCoronary Artery Disease | Quality of LifeUnited Kingdom
-
Peking University Third HospitalShengjing Hospital; Women's Hospital School Of Medicine Zhejiang University; The...Recruiting
-
AHS Cancer Control AlbertaCross Cancer InstituteRecruiting
-
Trans Tasman Radiation Oncology GroupActive, not recruitingBreast CancerAustralia, New Zealand
-
Maastricht University Medical CenterAlpro FoundationCompletedObesity, Insulin Sensitivity, Type 2 Diabetes MellitusNetherlands
-
University Hospital TuebingenCompletedHead and Neck CancerGermany